For most early-stage founders in the U.S. startup ecosystem, the answer is a SAFE: it is faster, simpler, and free of the repayment deadline and accumulating interest that come with a convertible note. But that default is not universal. A convertible note—a short-term loan designed to turn into equity at a later priced round—remains the better fit when investors insist on a structured, familiar debt instrument, or when a founder is raising a larger early-stage round. The right choice depends on your speed requirements, your investors' expectations, and your tolerance for debt obligations. This article maps those factors into a decision framework you can apply to your own round.
Understanding Early-Stage Funding: Convertible Notes and SAFEs
Both instruments exist to solve the same problem: letting a startup raise capital without setting a valuation up front. As Stripe explains, a convertible note is a short-term loan designed to turn into equity later, usually when the business raises its next priced funding round, while a SAFE—a Simple Agreement for Future Equity—gives an investor the right to receive equity in the future, typically at that same priced round. Both defer the valuation conversation to a moment when there is more data to support it.
The two instruments share the same core economic levers. According to Carta's comparison, both convertible notes and SAFEs can carry a valuation cap and a conversion discount. What separates them is everything else: the note is legally debt, it has a maturity date, and it accrues interest. The SAFE has none of those features. Those three differences drive nearly every practical consequence that follows.
Convertible Notes: Debt with a Future in Equity
A convertible note is, legally speaking, a loan. The startup borrows money from the investor with a promise that the principal will convert into equity at a future priced round rather than be repaid in cash. Because it is debt, the instrument carries the standard machinery of a loan: an interest rate and a maturity date.
Y Combinator, which created the SAFE as an alternative, summarizes the note's terms bluntly: interest "accrues (often 2–8%)," and the maturity date "can force repayment or default." That last phrase is the instrument's defining risk. If the startup has not raised a priced equity round by the time the note matures, the repayment obligation does not quietly disappear—the founders must repay, renegotiate, or face default. Interest compounds the issue: the accrued interest adds to the amount that converts into shares, increasing investor dilution of the founders at conversion.
The offsetting advantage is structure. Because the note is a familiar, legally established debt instrument, some investors—particularly those accustomed to traditional financing—prefer it. Stripe notes that the note provides investors with "a structured, familiar instrument," which can matter when you are negotiating with parties who want the protections debt affords.
SAFEs: Simple Agreements for Future Equity
A SAFE strips out the debt machinery entirely. It is a convertible security, not a loan: the investor pays money now in exchange for the right to equity later, and the startup takes on no repayment obligation. There is no maturity date and no interest, so the invested amount stays fixed until conversion.
That simplicity is the point. Y Combinator designed the SAFE to make early-stage fundraising faster and cheaper by removing the mechanics of debt, and the instrument is now used on standardized templates that require minimal customization. CRV, a venture firm that has published guidance on the choice, describes the practical effect: standard templates "let you close in days rather than weeks," and a SAFE can be signed in as little as 48 hours when speed matters.
CRV also highlights a second advantage of the post-money SAFE structure: predictable dilution. A $500,000 SAFE with a $10 million cap always represents five percent ownership, because the post-money cap fixes the investor's share of the company at the time of the SAFE, regardless of how much other money comes in around it. Founders can calculate their dilution before signing.
Key Distinctions and Their Practical Implications
The three structural differences between the instruments translate directly into founder risk and cost. The maturity date is the largest. A note that reaches maturity without a priced round puts the founders in a corner: they must find the cash to repay, persuade the investor to extend, or default. A SAFE never creates that moment. As Carta puts it, without a repayment deadline or accumulating interest, "founders can focus on building rather than managing debt."
Interest is the second cost. On a note, accrued interest rides along with the principal into the conversion, so the investor receives more shares than the cash they put in would otherwise buy. A SAFE's fixed amount avoids this entirely.
Legal priority is a subtler consequence. CRV notes that convertible notes convert before SAFEs due to their legal priority as debt instruments, which affects dilution calculations when a company has both outstanding. Mixing the two in a single cap table requires careful structuring, and most founders stick to one instrument type per round unless investor requirements force the mix.
Decision Framework: Choosing Your Funding Instrument
The framework below maps the five situational factors that matter most to the instrument each one favors. Answer each question honestly about your own round; the pattern of answers points to the instrument that fits.
| Situational question | If your answer is… | Lean toward | Why |
|---|---|---|---|
| How fast must the round close? | Days, not weeks | SAFE | Standardized templates need minimal customization and negotiation; CRV describes SAFEs closing in as little as 48 hours. |
| Who are your investors? | Angel investors and early-stage funds who prefer simplicity | SAFE | CRV reports most angels and early-stage funds now prefer SAFEs, especially former founders who raised on them. |
| Who are your investors? | Investors who want a structured, familiar debt instrument | Convertible note | Stripe notes the note provides investors a structured, familiar instrument with debt's protections. |
| How large is the round? | Larger early-stage amount | Convertible note | Wise's guidance identifies convertible notes as more suitable for founders raising larger early-stage rounds. |
| Can you tolerate a repayment obligation? | No—if no priced round happens, repayment or default is unacceptable | SAFE | SAFEs have no maturity date and no repayment obligation; notes can force repayment or default at maturity, per Y Combinator. |
| Do you want dilution fixed in advance? | Yes—predictable ownership at a known cap | Post-money SAFE | CRV's example: a $500K SAFE with a $10M cap always represents five percent ownership. |
| Do you want to avoid administrative overhead? | Yes—minimal legal cost and negotiation | SAFE | SAFEs were designed to remove debt mechanics and minimize legal costs, per Y Combinator and Wise. |
Read the pattern rather than any single row. A founder raising a modest pre-seed from angels who value speed gets a SAFE on nearly every answer. A founder raising a larger round from investors who insist on debt's structure may find the note's maturity and interest are the price of getting the money at all.
Two caveats govern the whole framework. First, this is not legal or tax advice—both instruments have consequences worth reviewing with counsel before signing. Second, these are the standard U.S. forms; individual terms can be customized, and negotiated notes or SAFEs may deviate from the defaults described here.
Making Your Choice: A Path Forward
Founders and investors should choose between a SAFE and a convertible note based on their specific fundraising goals, investor expectations, and tolerance for debt obligations, prioritizing simplicity and speed for early stages with SAFEs, or structured debt for later bridge rounds with convertible notes. The decision is rarely about which instrument is objectively better—it is about which one your situation can carry.
The measurable indicator that you have chosen well is concrete: the chosen instrument's terms are clearly understood by all parties, and the fundraising process aligns with the startup's strategic timeline. If you cannot explain to your co-founder, in one pass, what happens to the money at maturity or at conversion, you are not done evaluating the instrument. If your investors expect a note and you are offering a SAFE—or the reverse—expect friction that costs more time than the choice saves. Close only when the terms, the timeline, and the counterparty all point the same way.
